Eli Lilly is a $45B US pharmaceutical company headquartered in Indianapolis, founded in 1876.
Is this your business? Add your evidence →
Eli Lilly has renewable energy momentum but weak climate fundamentals. Scope 1 emissions rose 5.5% in 2024 despite carbon neutrality claims. No SBTi targets, no Scope 3 reduction plans, and active trade association opposition to climate policy undermine credibility. Greenwashing risk is material.
Eli Lilly and Company scores 39/100 (Below expectations) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified May 2026.
That places Eli Lilly and Company joint 385th of 847 companies scored, and joint 11th of 19 in Healthcare / Pharmaceuticals.
Where Eli Lilly and Company sits among healthcare / pharmaceuticals peers.
Among the 19 major healthcare / pharmaceuticals brands we've scored, Eli Lilly and Company is tied =11th of 19, with 3 others.
Its three lowest-scoring questions, and what the evidence didn't show.
No trade association climate alignment review published.
2030 carbon neutrality (Scope 1+2) and 100% renewable electricity targets are specific but critically exclude Scope 3 (~3.7Mt, >85% of total emissions).
37% combined Scope 1+2 reduction claimed 2020–2024, but Scope 1 rose 5.49% in 2024.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Carbon Footprint — Supply Chain (7/10, 6/10). Weakest on Controversies & Red Flags and Targets & Commitments (1/10, 3/10).
The 3 companies in the sector scoring nearest above Eli Lilly and Company.
AbbVie has achieved meaningful absolute emissions reductions and maintains science-aligned near-term climate targets, but obscures its full supply chain footprint and lacks net-zero validation.
See the breakdown →Philips demonstrates strong climate governance with SBTi-validated targets, 80% renewable energy, and A-list CDP scores across 11 years.
See the breakdown →The formula and all 15 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale15 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
8 of 15 sources are independent of the company.
If you believe a source has been misread or a newer version exists, submit a challenge.
Eli Lilly is a $45B US pharmaceutical company headquartered in Indianapolis, founded in 1876. A major player in therapeutics, vaccines, and animal health, the company manufactures across global sites and sources from complex supply chains. It operates in a sector facing rising scrutiny over environmental impact and access to medicines.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.